Breckenridge announces launch of Duloxetine Delayed-release Capsules

Published on June 12, 2014 at 3:35 PM · No Comments

Breckenridge Pharmaceutical, Inc. announced today the immediate launch of Duloxetine Delayed-release Capsules. The U.S. Food and Drug Administration granted final approval for the Abbreviated New Drug Application (ANDA), which is being manufactured and supplied by its parent company, Laboratorios Dr. Esteve, S.A. Barcelona, Spain, and will be available in 20mg, 30mg and 60mg strengths. Duloxetine Delayed-release Capsules are AB rated to Cymbalta®, a drug marketed by Eli Lilly, for the treatment of (MDD) Major Depressive Disorder. This milestone signifies the first vertically-integrated product developed and commercialized between Breckenridge and Esteve.

Source:

Breckenridge

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Avanir Pharmaceuticals to publish AVP-825 phase III study results in the journal 'Headache'